https://www.selleckchem.com/pr....oducts/epoxomicin-bu
More importantly, the addition of cellular immunotherapy considerably improved OS and DFS only in patients with stage III rather than stage II. In addition, we also discovered that the combined therapy did not cause intolerable side effects to patients. Cellular immunotherapy plus chemotherapy ameliorates survival in GC, especially in patients with stage III, implicating that it is a valuable therapeutic strategy for these patients.When radiologists search for a specific target (e.g., lung cancer), they are also asked to rep
Like
Comment
Share
